Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol(University of Michigan), Bernard M.J. Uitdehaag(Amsterdam UMC Location Vrije Universiteit Amsterdam), Patricia K. Coyle(St. Michael's Hospital), Peter Chang(St. Michael's Hospital), Steven R. Schwid(University of Rochester), Douglas Jeffery(University of New Mexico), Frederik Barkhof(Netherlands Institute for Neuroscience), Bettina Stubinski(Merck Serono S.A. (Switzerland))
Cited by 484
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k